CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.010
-0.040 (-3.81%)
Nov 4, 2024, 4:00 PM EST - Market closed
CytomX Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 119.57 | 101.21 | 53.16 | 37.31 | 68.43 | 26.9 | Upgrade
|
| Revenue Growth (YoY) | 50.41% | 90.38% | 42.48% | -45.47% | 154.36% | -54.79% | Upgrade
|
| Gross Profit | 119.57 | 101.21 | 53.16 | 37.31 | 68.43 | 26.9 | Upgrade
|
| Selling, General & Admin | 30.79 | 30.02 | 40.45 | 39.16 | 36.03 | 36.77 | Upgrade
|
| Research & Development | 83.06 | 77.68 | 106.55 | 114.19 | 112.94 | 131.62 | Upgrade
|
| Operating Expenses | 113.85 | 107.7 | 147 | 153.35 | 148.97 | 168.38 | Upgrade
|
| Operating Income | 5.72 | -6.48 | -93.84 | -116.04 | -80.54 | -141.48 | Upgrade
|
| Interest & Investment Income | 9.37 | 9.84 | 1.68 | 0.26 | 1.84 | 8.37 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.03 | 0.34 | -0.08 | -0.03 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | 15.08 | 3.32 | -91.82 | -115.87 | -78.73 | -133.25 | Upgrade
|
| Merger & Restructuring Charges | - | - | -7.5 | - | - | - | Upgrade
|
| Pretax Income | 15.08 | 3.32 | -99.32 | -115.87 | -78.73 | -133.25 | Upgrade
|
| Income Tax Expense | 3.99 | 3.89 | - | - | -13.91 | -0.43 | Upgrade
|
| Net Income | 11.09 | -0.57 | -99.32 | -115.87 | -64.82 | -132.83 | Upgrade
|
| Net Income to Common | 11.09 | -0.57 | -99.32 | -115.87 | -64.82 | -132.83 | Upgrade
|
| Shares Outstanding (Basic) | 82 | 74 | 66 | 64 | 46 | 45 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 74 | 66 | 64 | 46 | 45 | Upgrade
|
| Shares Change (YoY) | 24.87% | 12.27% | 2.48% | 39.01% | 1.79% | 8.81% | Upgrade
|
| EPS (Basic) | 0.13 | -0.01 | -1.51 | -1.81 | -1.40 | -2.93 | Upgrade
|
| EPS (Diluted) | 0.13 | -0.01 | -1.51 | -1.81 | -1.40 | -2.93 | Upgrade
|
| Free Cash Flow | -86.29 | -56.88 | -112.53 | -120.64 | 2.95 | -143.98 | Upgrade
|
| Free Cash Flow Per Share | -1.04 | -0.77 | -1.71 | -1.88 | 0.06 | -3.18 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 4.79% | -6.41% | -176.50% | -311.00% | -117.70% | -525.92% | Upgrade
|
| Profit Margin | 9.27% | -0.56% | -186.82% | -310.54% | -94.73% | -493.74% | Upgrade
|
| Free Cash Flow Margin | -72.16% | -56.19% | -211.67% | -323.33% | 4.31% | -535.19% | Upgrade
|
| EBITDA | 7.62 | -4.31 | -91.39 | -113.34 | -77.97 | -138.88 | Upgrade
|
| EBITDA Margin | 6.37% | -4.26% | -171.91% | - | -113.94% | - | Upgrade
|
| D&A For EBITDA | 1.9 | 2.18 | 2.44 | 2.71 | 2.57 | 2.61 | Upgrade
|
| EBIT | 5.72 | -6.48 | -93.84 | -116.04 | -80.54 | -141.48 | Upgrade
|
| EBIT Margin | 4.79% | -6.41% | -176.50% | - | -117.70% | - | Upgrade
|
| Effective Tax Rate | 26.48% | 117.12% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.